HealthTronics Plans 300-Patient Postmarket Study Of OssaTron For Heel Pain
This article was originally published in The Gray Sheet
Executive Summary
HealthTronics is planning a 300-patient, 12-week post-market study of the OssaTron orthopedic lithotriptor for treatment of plantar fasciitis (heel spurs), following FDA approval of the device Oct. 12.
You may also be interested in...
HealthTronics Class Action Swells; Firm Launches OssaTron Training Effort
HealthTronics will embark on an aggressive OssaTron marketing campaign to convince payors that the heel spur pain treatment deserves reimbursement
HealthTronics Class Action Swells; Firm Launches OssaTron Training Effort
HealthTronics will embark on an aggressive OssaTron marketing campaign to convince payors that the heel spur pain treatment deserves reimbursement
HealthTronics' OssaTron Lithotriptor Approvable For Heel Spur Pain - Panel
HealthTronics' OssaTron orthopedic lithotriptor should be approved for treatment of plantar fasciitis (heel spurs), rather than the more general indication of chronic heel pain syndrome, FDA's Orthopedic and Rehabilitation Devices Panel suggested.